मूलभूत आँकड़े
| CIK | 1831828 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Vera Therapeutics, Inc.
SEC Filings (Chronological Order)
यह पृष्ठ SEC फाइलिंग की एक पूरी, कालानुक्रमिक सूची प्रदान करता है, ओनरशिप फाइलिंग को छोड़कर, जो हम अन्यत्र प्रदान करते हैं।
| August 5, 2025 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Vera Therapeutics, Inc. |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2025 Vera Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40407 81-2744449 (State or other jurisdiction of incorporation) (Commission |
|
| August 5, 2025 |
Vera Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results Exhibit 99.1 Vera Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results • On track to submit a Biologics License Application (BLA) for accelerated approval of atacicept to U.S. FDA in Q4 2025; potential commercial launch in 2026 • Announced positive primary endpoint results from the ongoing ORIGIN Phase 3 trial • Initiated the PIONEER trial to investigate atacicep |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40407 Vera Thera |
|
| August 5, 2025 |
Up to $200,000,000 Class A Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-282861 PROSPECTUS SUPPLEMENT (to Prospectus dated October 28, 2024) Up to $200,000,000 Class A Common Stock We have entered into a sales agreement, or the sales agreement, with TD Securities (USA) LLC, or TD Cowen, dated as of August 5, 2025, relating to the sale of shares of our Class A common stock, par value $0.001 pe |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2025 Vera Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40407 81-2744449 (State or other jurisdiction of incorporation) (Commission |
|
| August 5, 2025 |
EX-1.1 Exhibit 1.1 VERA THERAPEUTICS, INC. $200,000,000 CLASS A COMMON STOCK SALES AGREEMENT August 5, 2025 TD Securities (USA) LLC 1 Vanderbilt Avenue New York, New York 10017 Ladies and Gentlemen: Vera Therapeutics, Inc. (the “Company”), confirms its agreement (this “Agreement”) with TD Securities (USA) LLC (“TD Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from t |
|
| June 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2025 Vera Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40407 81-2744449 (State or other jurisdiction of incorporation) (Commission Fi |
|
| June 3, 2025 |
EX-10.1 Exhibit 10.1 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (as the same may from time to time be amended, modified, supplemented or restated, this “Agreement”) dated as of June 2, 2025 (the “Signing Date”), among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, VA 22314 (“Oxford”), as collateral |
|
| June 2, 2025 |
Exhibit 99.1 Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy • Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria (UPCR) at week 36; patients receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared to placebo at week 36 (p<0.0001) • Other prespecified endpo |
|
| June 2, 2025 |
Exhibit 99.2 ORIGIN Phase 3 Topline Results June 2, 2025 © 2025 Vera Therapeutics, Inc. Corporate Presentation. Forward-looking statements Disclaimer This material has been made available to you with the consent of Vera Therapeutics, Inc. ( we , us , our , or the Company ). Statements in this presentation that are not statements of historical fact are forward-looking statements within the meaning |
|
| June 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2025 Vera Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40407 81-2744449 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 19, 2025 |
FORM 8-K Item 5.07 Submission of Matters to a Vote of Security Holders. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 Vera Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40407 81-2744449 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40407 Vera Ther |
|
| May 6, 2025 |
Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results Exhibit 99.1 Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results • On track to announce the primary endpoint results from the atacicept pivotal Phase 3 ORIGIN trial in IgA Nephropathy (IgAN) in 2Q 2025; planning for Biologics License Application (BLA) submission for atacicept accelerated approval to the U.S. FDA in 4Q 2025 • Expanded atacicept development pr |
|
| May 6, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2025 Vera Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40407 81-2744449 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 3, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Co |
|
| April 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| February 28, 2025 |
Vera Therapeutics, Inc. Insider Trading Policy. Exhibit 19.1 Vera Therapeutics, Inc. Insider Trading Policy 1. Introduction During the course of your relationship with Vera Therapeutics, Inc. (the “Company”), you may receive material information that is not yet public (“material nonpublic information”) about the Company or about other publicly traded companies. Material nonpublic information may give you, or someone you pass that information on |
|
| February 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K . UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 001-40407 Vera Therapeu |
|
| February 28, 2025 |
Offer Letter, by and between the Registrant and Jason Carter, dated November 4, 2024. Exhibit 10.24 November 4, 2024 Jason Carter Re: Revised Employment Terms Dear Jason: On behalf of Vera Therapeutics, Inc. (the “Company”), I am pleased to offer you employment at the Company on the terms set forth in this offer letter agreement (this “Agreement”). As discussed, the terms of this Agreement govern with respect to your employment, which shall commence on November 18, 2024 (such actua |
|
| February 28, 2025 |
Vera Therapeutics, Inc. Non-employee Director Compensation Policy, as amended December 9, 2024. Exhibit 10.11 Vera Therapeutics, Inc. Non-Employee Director Compensation Policy Amended and Restated Effective January 1, 2025 Each member of the Board of Directors (the “Board”) of Vera Therapeutics, Inc. (the “Company”) who is not also serving as an employee of the Company or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Em |
|
| February 28, 2025 |
Exhibit 10.7 Vera Therapeutics, Inc. 2024 Inducement Plan Adopted by the Compensation Committee of the Board of Directors: February 3, 2024 Amended by the Compensation Committee of the Board of Directors: August 28, 2024 Amended by the Compensation Committee of the Board of Directors: January 28, 2025 1. General. (a) Eligible Award Recipients. The only persons eligible to receive grants of Awards |
|
| February 28, 2025 |
Vera Therapeutics, Inc. 2021 Non-employee Director Compensation Policy, as amended on May 2, 2024. Exhibit 10.10 Vera Therapeutics, Inc. Non-Employee Director Compensation Policy Amended and Restated Effective May 2, 2024 Each member of the Board of Directors (the “Board”) of Vera Therapeutics, Inc. (the “Company”) who is not also serving as an employee of the Company or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employ |
|
| February 28, 2025 |
As filed with the Securities and Exchange Commission on February 28, 2025 As filed with the Securities and Exchange Commission on February 28, 2025 Registration No. |
|
| February 28, 2025 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Vera Therapeutics, Inc. |
|
| February 26, 2025 |
Exhibit 99.1 Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results • On track to announce the primary endpoint result from the atacicept pivotal Phase 3 ORIGIN trial in IgA Nephropathy (IgAN) in 2Q 2025; BLA submission to the U.S. FDA for accelerated approval planned in 2H 2025 • Expanded atacicept clinical development program in multiple autoim |
|
| February 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2025 Vera Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40407 81-2744449 (State or other jurisdiction of incorporation) (Commissi |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 Vera Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40407 81-2744449 (State or other jurisdiction of incorporation) (Commissio |
|
| January 13, 2025 |
Exhibit 99.1 J.P. Morgan Healthcare Conference January 13, 2025 © 2025 VERA THERAPEUTICS, INC. Forward-looking statements Disclaimer This material has been made available to you with the consent of Vera Therapeutics, Inc. ( we , us , our , or the Company ). Statements in this presentation that are not statements of historical fact are forward-looking statements within the meaning of the Private Se |
|
| November 14, 2024 |
SC 13G/A 1 veraa2111424.htm KYNAM CAPITAL MANAGEMENT, LP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Vera Therapeutics, Inc. (Name of Issuer) Class A common stock, $0.001 par value per share (Title of Class of Securities) 92337R101 (CUSIP Number) September 30, 2024 (Date of Event which Requires Fi |
|
| November 14, 2024 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) EXHIBIT 1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. |
|
| November 14, 2024 |
SC 13G 1 p24-3170sc13g.htm VERA THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Vera Therapeutics, Inc. (Name of Issuer) Class A Common Stock, $0.001 par value per share (Title of Class of Securities) 92337R101 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statemen |
|
| November 14, 2024 |
VERA / Vera Therapeutics, Inc. / COMMODORE CAPITAL LP Passive Investment SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Vera Therapeutics, Inc. (Name of Issuer) Class A common stock, $0.001 par value per share (Title of Class of Securities) 92337R101 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the |
|
| November 14, 2024 |
VERA / Vera Therapeutics, Inc. / COMMODORE CAPITAL LP Passive Investment SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Vera Therapeutics, Inc. (Name of Issuer) Class A common stock, $0.001 par value per share (Title of Class of Securities) 92337R101 (CUSIP Number) February 29, 2024 (Date of Event Which Requires Filing of this Statement) Check the |
|
| November 7, 2024 |
Vera Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results Exhibit 99.1 Vera Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results • Presented positive 96-week long-term eGFR stabilization data from ORIGIN Ph 2b clinical trial of atacicept in IgAN in a late-breaking oral presentation at the American Society of Nephrology (ASN) Kidney Week 2024 with simultaneous peer-reviewed publication in the Journal of the American Socie |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40407 Vera |
|
| November 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 Vera Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40407 81-2744449 (State or other jurisdiction of incorporation) (Commissio |
|
| November 7, 2024 |
Vera Therapeutics, Inc. 2024 Inducement Plan, as amended. Exhibit 10.2 Vera Therapeutics, Inc. 2024 Inducement Plan Adopted by the Compensation Committee of the Board of Directors: February 3, 2024 Amended by the Compensation Committee of the Board of Directors: August 28, 2024 1. General. (a) Eligible Award Recipients. The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the standards for inducement grants un |
|
| November 4, 2024 |
VERA / Vera Therapeutics, Inc. / Longitude Capital Partners IV, LLC - SC 13D/A Activist Investment SC 13D/A 1 d811011dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4) VERA THERAPEUTICS, INC. (Name of Issuer) Class A Common Stock, $0.001 par value per share (Title of Class of Securities) 92337R101 (CUSIP Number) Patrick G. Enright Managing Member Longitude Capital Partners IV, LLC |
|
| October 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2024 Vera Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40407 81-2744449 (State or other jurisdiction of incorporation) (Commissio |
|
| October 31, 2024 |
Exhibit 1.1 Execution Version VERA THERAPEUTICS, INC. 7,142,858 Shares of Class A Common Stock Underwriting Agreement October 29, 2024 J.P. Morgan Securities LLC Goldman Sachs & Co. LLC Evercore Group L.L.C. Cantor Fitzgerald & Co. As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Goldman Sac |
|
| October 30, 2024 |
PROSPECTUS Class A Common Stock Preferred Stock Debt Securities Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333- 282861 Prospectus supplement (To prospectus dated October 28, 2024) 7,142,858 shares Class A common stock We are offering 7,142,858 shares of our Class A common stock. Our Class A common stock is traded on the Nasdaq Global Market under the symbol “VERA.” On October 25, 2024, the last reported sale price of our Class A common |
|
| October 30, 2024 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Vera Therapeutics, Inc. |
|
| October 29, 2024 |
424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333- 282861 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer t |
|
| October 28, 2024 |
Exhibit 99.2 Virtual Investor Event to Discuss Long-Term Results from the Phase 2b ORIGIN Study of Atacicept in IgAN Presented at ASN Kidney Week 2024 October 28, 2024 © 2024 VERA THERAPEUTICS, INC. Forward-looking statements Disclaimer This material has been made available to you with the consent of Vera Therapeutics, Inc. ( we , us , our , or the Company ). Statements contained in this presentat |
|
| October 28, 2024 |
As filed with the Securities and Exchange Commission on October 28, 2024 Table of Contents As filed with the Securities and Exchange Commission on October 28, 2024 Registration No. |
|
| October 28, 2024 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate. Exhibit 4.7 VERA THERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF VERA THERAPEUTICS, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between VERA THERAPEUTICS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and ex |
|
| October 28, 2024 |
Form of Class A Common Stock Warrant Agreement and Warrant Certificate. Exhibit 4.6 VERA THERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF CLASS A COMMON STOCK WARRANT AGREEMENT DATED AS OF VERA THERAPEUTICS, INC. FORM OF CLASS A COMMON STOCK WARRANT AGREEMENT THIS CLASS A COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between VERA THERAPEUTICS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] o |
|
| October 28, 2024 |
Form of Indenture, by and between the Registrant and one or more trustees to be named. Exhibit 4.3 VERA THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20 Debt Securities TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate 8 S |
|
| October 28, 2024 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Vera Therapeutics, Inc. |
|
| October 28, 2024 |
Exhibit 99.1 Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024 • Long-term improvements observed in the quartet of findings defining disease modification supports atacicept’s potential to prevent kidney failure in patients with IgAN; • Long-term results fro |
|
| October 28, 2024 |
Form of Debt Securities Warrant Agreement and Warrant Certificate. Exhibit 4.8 VERA THERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF VERA THERAPEUTICS, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between VERA THERAPEUTICS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organ |
|
| October 28, 2024 |
Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2024 Vera Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40407 81-2744449 (State or other jurisdiction of incorporation) (Commissio |
|
| October 2, 2024 |
Exhibit 99.1 Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases • PIONEER study expands the investigation of atacicept into a broad definition of IgA nephropathy and into multiple autoimmune glomerular diseases, supported by the disease-modifying potential of BAFF/APRIL dual inhibition; • Multiple regulatory and clinical milestones expected ov |
|
| October 2, 2024 |
Exhibit 99.2 R&D Day October 2, 2024 © 2024 VERA THERAPEUTICS, INC. Forward-looking statements Disclaimer This material has been made available to you with the consent of Vera Therapeutics, Inc. ( we , us , our , or the Company ). Statements in this presentation that are not statements of historical fact are forward-looking statements within the meaning of the Private Securities Litigation Reform |
|
| October 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2024 Vera Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40407 81-2744449 (State or other jurisdiction of incorporation) (Commission |
|
| August 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 Vera Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40407 81-2744449 (State or other jurisdiction of incorporation) (Commission |
|
| August 8, 2024 |
Vera Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results Exhibit 99.1 Vera Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results • Received FDA Breakthrough Therapy Designation for atacicept in IgA Nephropathy (IgAN) • Presented data from Phase 2b ORIGIN study at ERA24 Congress showing atacicept stabilized kidney function through 72 weeks and led to rapid reductions in hematuria • Topline 96-week data from Phase 2b ORIG |
|
| August 8, 2024 |
Offer Letter, by and between the Registrant and David Johnson, dated June 26, 2024 June 26, 2024 REVISED David Johnson Re: Employment Terms Dear David: On behalf of Vera Therapeutics, Inc. |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40407 Vera Thera |
|
| July 2, 2024 |
Offer Letter, by and between the Company and David Johnson, dated June 26, 2024. Exhibit 10.1 June 26, 2024 REVISED David Johnson Re: Employment Terms Dear David: On behalf of Vera Therapeutics, Inc. (the “Company”), I am pleased to offer you employment at the Company on the terms set forth in this offer letter agreement (this “Agreement”). As discussed, the terms of this Agreement govern with respect to your employment, which shall commence no later than July 1, 2024 (such ac |
|
| July 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2024 Vera Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40407 81-2744449 (State or other jurisdiction of incorporation) (Commission F |
|
| June 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2024 Vera Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40407 81-2744449 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 17, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024 Vera Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40407 81-2744449 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 10, 2024 |
Offer Letter, by and between the Registrant and William Turner, dated December 19, 2023. Exhibit 10.3 December 19, 2023 William Turner Re: Employment Terms Dear William: On behalf of Vera Therapeutics, Inc. (the “Company”), I am pleased to offer you employment at the Company on the terms set forth in this offer letter agreement (this “Agreement”). As discussed, the terms of this Agreement govern with respect to your employment, which shall commence no later than January 8, 2024 (such |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40407 Vera Ther |
|
| May 10, 2024 |
Offer Letter, by and between the Registrant and Robert Brenner, M.D., dated January 3, 2024. Exhibit 10.2 January 3, 2024 Robert Brenner, M.D. Re: Employment Terms Dear Robert: On behalf of Vera Therapeutics, Inc. (the “Company”), I am pleased to offer you employment at the Company on the terms set forth in this offer letter agreement (this “Agreement”). As discussed, the terms of this Agreement govern with respect to your employment, which shall commence no later than January 8, 2024 (su |
|
| May 9, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 Vera Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40407 81-2744449 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 9, 2024 |
Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results Exhibit 99.1 Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results • Presented positive 72-week data from the Phase 2b ORIGIN clinical trial, setting a new standard in IgAN with no loss of kidney function over the duration of treatment • Topline 96-week data from ORIGIN 2 trial expected in Q4 2024 • Pivotal Phase 3 ORIGIN 3 trial estimated to complete enrollme |
|
| May 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| April 3, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permit |
|
| March 27, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Vera Therapeutics, Inc. |
|
| March 27, 2024 |
Vera Therapeutics, Inc. 2024 Inducement Plan. Exhibit 10.7 INDUCEMENT PLAN Vera Therapeutics, Inc. 2024 Inducement Plan Adopted by the Board of Directors: February 2, 2024 1. General. (a) Eligible Award Recipients. The only persons eligible to receive grants of Awards under this Plan are individuals who satisfy the standards for inducement grants under Nasdaq Marketplace Rule 5635(c)(4) or 5635(c)(3), if applicable, and the related guidance u |
|
| March 27, 2024 |
Exhibit 4.3 DESCRIPTION OF COMMON STOCK General The following description summarizes the terms of the Class A common stock and Class B common stock of Vera Therapeutics, Inc., or we, our or us. Because it is only a summary, it does not contain all the information that may be important to you. For a complete description of the matters set forth in this “Description of Common Stock,” you should refe |
|
| March 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K . UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 001-40407 Vera Therapeu |
|
| March 27, 2024 |
Vera Therapeutics, Inc. Incentive Compensation Recoupment Policy Exhibit 97.1 VERA THERAPEUTICS, INC. INCENTIVE COMPENSATION RECOUPMENT POLICY As adopted on November 6, 2023 1. INTRODUCTION The Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of Vera Therapeutics, Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive C |
|
| March 27, 2024 |
Vera Therapeutics, Inc. Non-employee Director Compensation Policy, as amended December 6, 2023. Exhibit 10.11 Vera Therapeutics, Inc. Non-Employee Director Compensation Policy Amended and Restated Effective January 1, 2024 Each member of the Board of Directors (the “Board”) of Vera Therapeutics, Inc. (the “Company”) who is not also serving as an employee of the Company or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Em |
|
| March 27, 2024 |
As filed with the Securities and Exchange Commission on March 27, 2024 As filed with the Securities and Exchange Commission on March 27, 2024 Registration No. |
|
| March 27, 2024 |
Separation Agreement by and between the Registrant and Celia Lin, M.D., dated January 3, 2024. Exhibit 10.14 January 3, 2024 Celia Lin, M.D. Via Email Dear Celia: This letter sets forth the substance of the separation agreement (the “Agreement”) that Vera Therapeutics, Inc. (the “Company”) is offering to you to aid in your employment transition. By executing and delivering this Agreement, you and the Company agree as follows: 1. SEPARATION. Your last day of employment with the Company will |
|
| March 27, 2024 |
Exhibit 10.9 VERA THERAPEUTICS, INC. 2024 INDUCEMENT PLAN RESTRICTED STOCK UNIT GRANT NOTICE Vera Therapeutics, Inc. (the “Company”) has awarded to you (the “Participant”) the number of restricted stock units specified, and on the terms set forth, below in consideration of your future services (the “RSU Award”). Your RSU Award is subject to all of the terms and conditions as set forth herein, in t |
|
| March 27, 2024 |
EXHIBIT 10.8 VERA THERAPEUTICS, INC. STOCK OPTION GRANT NOTICE (2024 INDUCEMENT PLAN) Vera Therapeutics, Inc. (the “Company”), pursuant to its 2024 Inducement Plan (as may be amended and/or restated as of the Date of Grant set forth below, the “Plan”), has granted to Optionholder an Option to purchase the number of shares of the Common Stock set forth below (the “Option”) as an inducement material |
|
| March 26, 2024 |
VERA / Vera Therapeutics, Inc. / Sofinnova Venture Partners X, L.P. - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (RULE 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 4)* Vera Therapeutics, Inc. (Name of Issuer) Class A Common Stock, $0.001 par value (Title of Class of Securities) 92337R101 (CUSIP Number) Nathalie Auber Sofinnova Invest |
|
| March 20, 2024 |
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results • Presented positive 72-week data from the Phase 2b ORIGIN clinical trial, setting a new standard in IgAN with no loss of kidney function over the duration of treatment • Actively adding sites and enrolling pivotal Phase 3 ORIGIN 3 study of atacicept for the treatment of IgAN; topline data expected in 1H 2025 • Completed $287. |
|
| March 20, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2024 Vera Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40407 81-2744449 (State or other jurisdiction of incorporation) (Commission |
|
| February 20, 2024 |
VERA / Vera Therapeutics, Inc. / Sofinnova Venture Partners X, L.P. - SC 13D/A Activist Investment SC 13D/A 1 tm246499d5sc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (RULE 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 3)* Vera Therapeutics, Inc. (Name of Issuer) Class A Common Stock, $0.001 par value (Title of Class of Securities) 92337R101 (CUSI |
|
| February 14, 2024 |
VERA / Vera Therapeutics, Inc. / Ares Trading S.A. - SC 13G/A Passive Investment SC 13G/A 1 tm246283d2sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 2)* Vera Therapeutics, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 92337R |
|
| February 14, 2024 |
VERA / Vera Therapeutics, Inc. / COMMODORE CAPITAL LP Passive Investment SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.1)* Vera Therapeutics, Inc. (Name of Issuer) Class A common stock, $0.001 par value per share (Title of Class of Securities) 92337R101 (CUSIP Number) June 14, 2023 (Date of Event Which Requires Filing of this Statement) Check the appro |
|
| February 14, 2024 |
VERA / Vera Therapeutics, Inc. / CITADEL ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A 1 tm243573d15sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 3)* Vera Therapeutics, Inc. (Name of Issuer) Class A common stock, par value $0.001 per share (the “S |
|
| February 14, 2024 |
VERA / Vera Therapeutics, Inc. / COMMODORE CAPITAL LP Passive Investment SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Vera Therapeutics, Inc. (Name of Issuer) Class A common stock, $0.001 par value per share (Title of Class of Securities) 92337R101 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the |
|
| February 14, 2024 |
EX-99.2 3 tm246283d2ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 POWER OF ATTORNEY E. Merck KG, Darmstadt, Germany (the “Company”), hereby makes, constitutes and appoints each of Dr. Matthias Mülllenbeck, MBA, Jens Eckhardt, Kristin Eibisch and Johannes Eckhardt, or any of them acting singly, and with full power of substitution and re-substitution, the Company’s true and lawful attorney-in-fact (each of s |
|
| February 14, 2024 |
SC 13G/A 1 veraa121424.htm KYNAM CAPITAL MANAGEMENT, LP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Vera Therapeutics, Inc. (Name of Issuer) Class A common stock, $0.001 par value per share (Title of Class of Securities) 92337R101 (CUSIP Number) December 31, 2023 (Date of Event which Requires Fili |
|
| February 14, 2024 |
EX-99.1 2 tm246283d2ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) of the Securities Exchange Act of 1934, as amended, each of the undersigned agrees to the joint filing on behalf of each of them of the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the share capital of Vera Therapeutics, Inc . This Joint Filing Agreemen |
|
| February 12, 2024 |
VERA / Vera Therapeutics, Inc. / Woodline Partners LP Passive Investment SC 13G 1 p24-0709sc13g.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Vera Therapeutics, Inc. (Name of Issuer) Class A Common Stock, par value $0.001 per share (Title of Class of Securities) 92337R101 (CUSIP Number) December 31, 2023 (Date of event which requires filing of this statement) Check the appropriate b |
|
| February 5, 2024 |
VERA / Vera Therapeutics, Inc. / Longitude Capital Partners IV, LLC - SC 13D/A Activist Investment SC 13D/A 1 d672032dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3) VERA THERAPEUTICS, INC. (Name of Issuer) Class A Common Stock, $0.001 par value per share (Title of Class of Securities) 92337R101 (CUSIP Number) Patrick G. Enright Managing Member Longitude Capital Partners IV, LLC |
|
| January 30, 2024 |
Exhibit 1.1 Execution Version VERA THERAPEUTICS, INC. 8,064,517 Shares of Class A Common Stock Underwriting Agreement January 29, 2024 J.P. Morgan Securities LLC Cowen and Company, LLC Evercore Group L.L.C. As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Cowen and Company, LLC 599 Lexington Av |
|
| January 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2024 Vera Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40407 81-2744449 (State or other jurisdiction of incorporation) (Commissio |
|
| January 30, 2024 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Nos. 333-265408 and 333-276761 Prospectus supplement (To prospectus dated June 13, 2022) 8,064,517 shares Class A common stock We are offering 8,064,517 shares of our Class A common stock. Our Class A common stock is traded on the Nasdaq Global Market under the symbol “VERA.” On January 26, 2024, the last reported sale price of our Cl |
|
| January 29, 2024 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Vera Therapeutics, Inc. |
|
| January 29, 2024 |
As filed with the Securities and Exchange Commission on January 29, 2024 As filed with the Securities and Exchange Commission on January 29, 2024 Registration No. |
|
| January 29, 2024 |
Table of Contents The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| January 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2024 Vera Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40407 81-2744449 (State or other jurisdiction of incorporation) (Commissio |
|
| January 25, 2024 |
Exhibit 99.2 R&D Day January 25, 2024 © 2024 VERA THERAPEUTICS, INC. Forward-Looking Statements Disclaimer This material has been made available to you with the consent of Vera Therapeutics, Inc. ( we , us , our , or the Company ). Statements contained in this presentation regarding matters, events or results that may occur in the future are “forward-looking statements” within the meaning of the P |
|
| January 25, 2024 |
Exhibit 99.1 Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy – Participants treated with atacicept for 72 weeks showed consistent and sustained reductions in Gd-IgA1, hematuria, and UPCR, with stable eGFR over the duration of treatment – Placebo cohort participants who crossed over to atacicept 150 mg in the O |
|
| January 25, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2024 Vera Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40407 81-2744449 (State or other jurisdiction of incorporation) (Commissio |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2024 Vera Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40407 81-2744449 (State or other jurisdiction of incorporation) (Commission |
|
| January 8, 2024 |
EX-99.1 Exhibit 99.1 Vera Therapeutics Announces Appointment of Industry Veterans Robert Brenner, M.D. as Chief Medical Officer and William D. Turner as Chief Development Officer BRISBANE, Calif., January 8, 2024 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company developing and commercializing transformative treatments for patients with serious i |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 Vera Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40407 81-2744449 (State or other jurisdiction of incorporation) (Commission |
|
| January 8, 2024 |
Exhibit 99.1 Corporate Presentation January 2024 © 2023 VERA THERAPEUTICS, INC. Forward Looking Statements Disclaimer This material has been made available to you with the consent of Vera Therapeutics, Inc. ( we , us , our , or the Company ). Statements in this presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without l |
|
| December 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2023 Vera Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40407 81-2744449 (State or other jurisdiction of incorporation) (Commissi |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40407 Vera |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 Vera Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40407 81-2744449 (State or other jurisdiction of incorporation) (Commissio |
|
| November 9, 2023 |
Vera Therapeutics Provides Business Update and Reports Third Quarter Financial Results Exhibit 99.1 Vera Therapeutics Provides Business Update and Reports Third Quarter Financial Results • Phase 2b open-label extension eGFR and proteinuria data expected in the first quarter of 2024; actively adding sites and enrolling pivotal Phase 3 ORIGIN 3 study of atacicept in IgAN • Announced analysis of Phase 2b ORIGIN study showing resolution of hematuria in the majority of patients, at the A |
|
| August 10, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 Vera Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40407 81-2744449 (State or other jurisdiction of incorporation) (Commission |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40407 Vera Thera |
|
| August 10, 2023 |
Vera Therapeutics Provides Business Update and Reports Second Quarter Financial Results Exhibit 99.1 Vera Therapeutics Provides Business Update and Reports Second Quarter Financial Results • Presented positive 36-week results from the Phase 2b ORIGIN clinical trial of atacicept in IgAN as a late breaking clinical trial at the 60th ERA Congress • Initiated Phase 3 ORIGIN 3 clinical trial of atacicept in June for the treatment of IgAN • Strong balance sheet expected to fund operations |
|
| August 2, 2023 |
VERA / Vera Therapeutics Inc - Class A / Carlyle Group Inc. - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* Vera Therapeutics, Inc. (Name of Issuer) Class A Common Stock, par value $0.001 per share (Title of Class of Securities) 92337R101 (CUSIP Number) Jeffrey Ferguson The Carlyle Group 1001 Pennsylvania Avenue, NW Suite 220 South Washington, D.C. 20004 (202) 729- |
|
| July 5, 2023 |
VERA / Vera Therapeutics Inc - Class A / Carlyle Group Inc. - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Vera Therapeutics, Inc. (Name of Issuer) Class A Common Stock, par value $0.001 per share (Title of Class of Securities) 92337R101 (CUSIP Number) Jeffrey Ferguson The Carlyle Group 1001 Pennsylvania Avenue, NW Suite 220 South Washington, D.C. 20004 (202) 729- |
|
| June 20, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2023 Vera Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40407 81-2744449 (State or other jurisdiction of incorporation) (Commission F |
|
| June 20, 2023 |
EX-99.1 Exhibit 99.1 Corporate Presentation June 2023 © 2023 VERA THERAPEUTICS, INC. Forward Looking Statements Disclaimer This material has been made available to you with the consent of Vera Therapeutics, Inc. ( we , us , our , or the Company ). Statements in this presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, with |
|
| May 17, 2023 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2023 Vera Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40407 81-2744449 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 Vera Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40407 81-2744449 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40407 Vera Ther |
|
| May 11, 2023 |
Vera Therapeutics Provides Business Update and Reports First Quarter Financial Results Exhibit 99.1 Vera Therapeutics Provides Business Update and Reports First Quarter Financial Results • 36-week data from the Phase 2b ORIGIN clinical trial of atacicept in IgAN selected for presentation as a late breaking clinical trial at ERA Congress 2023 • Plan to initiate a pivotal Phase 3 clinical trial of atacicept in IgAN during the second quarter of 2023 • Strong balance sheet expected to f |
|
| April 13, 2023 |
VERA / Vera Therapeutics Inc - Class A / Carlyle Group Inc. - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Vera Therapeutics, Inc. (Name of Issuer) Class A Common Stock, par value $0.001 per share (Title of Class of Securities) 92337R101 (CUSIP Number) Jeffrey Ferguson The Carlyle Group 1001 Pennsylvania Avenue, NW Suite 220 South Washington, D.C. 20004 (202) 729- |
|
| March 30, 2023 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 30, 2023 |
TABLE OF CONTENTS SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 28, 2023 |
Power of Attorney (included on the signature page). S-8 As filed with the Securities and Exchange Commission on March 28, 2023 Registration No. |
|
| March 28, 2023 |
. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 001-40407 Vera Therapeu |
|
| March 28, 2023 |
Exhibit 4.3 DESCRIPTION OF COMMON STOCK General The following description summarizes the terms of the Class A common stock and Class B common stock of Vera Therapeutics, Inc., or we, our or us. Because it is only a summary, it does not contain all the information that may be important to you. For a complete description of the matters set forth in this “Description of Common Stock,” you should refe |
|
| March 28, 2023 |
Exhibit 10.7 Vera Therapeutics, Inc. Non-Employee Director Compensation Policy Amended and Restated March 28, 2023 Each member of the Board of Directors (the “Board”) of Vera Therapeutics, Inc. (the “Company”) who is not also serving as an employee of the Company or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Direc |
|
| March 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2023 Vera Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40407 81-2744449 (State or other jurisdiction of incorporation) (Commission |
|
| March 28, 2023 |
Exhibit 99.1 Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results • Announced positive interim data from the Phase 2b ORIGIN clinical trial of atacicept in IgAN, which showed a 41% mean reduction in proteinuria versus baseline in the 150mg dose group at 24 weeks • 36-week data from the Phase 2b ORIGIN clinical trial of atacicept in IgAN on trac |
|
| March 28, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Vera Therapeutics, Inc. |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 Vera Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40407 81-2744449 (State or other jurisdiction of incorporation) (Commission |
|
| February 16, 2023 |
SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) VERA THERAPEUTICS, INC. (Name of Issuer) Class A Common Stock, $0.001 par value per share (Title of Class of Securities) 92337R101 (CUSIP Number) Patrick G. Enright Managing Member Longitude Capital Partners IV, LLC 2740 Sand Hill Road, 2nd Floor Menlo Park, C |
|
| February 16, 2023 |
VERA / Vera Therapeutics, Inc. Class A / COMMODORE CAPITAL LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 16, 2023 |
EX-99.1 Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned, and any amendments thereto executed by the undersigned shall be filed on behalf of each of the undersigned without the necessity of filing any additional joint filing agreement. The undersigned acknowledge that each is responsible for the |
|
| February 14, 2023 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (RULE 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 2)* Vera Therapeutics, Inc. (Name of Issuer) Class A Common Stock, $0.001 par value (Title of Class of Securities) 92337R101 (CUSIP Number) Nathalie Auber Sofinnova Invest |
|
| February 14, 2023 |
VERA / Vera Therapeutics, Inc. Class A / CITADEL ADVISORS LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 2)* Vera Therapeutics, Inc. (Name of Issuer) Class A Common Stock, par value $0.001 per share (the “Shares”) (Title of Class of Securities) 923 |
|
| February 14, 2023 |
VERA / Vera Therapeutics, Inc. Class A / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm236221d13sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* VERA THERAPEUTICS, INC. (Name of Issuer) Class A Common Stock, par value $0.001 per share (Title of Class of Securities) 92337R101 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this S |
|
| February 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Vera Therapeutics, Inc. (Name of Issuer) CLASS A COMMON STOCK (Title of Class of Securities) 92337R101 (CUSIP Number) December 30, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| February 6, 2023 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (RULE 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 1)* Vera Therapeutics, Inc. (Name of Issuer) Class A Common Stock, $0.001 par value (Title of Class of Securities) 92337R101 (CUSIP Number) Nathalie Auber Sofinnova Invest |
|
| February 3, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 1)* Vera Therapeutics, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 92337R101 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filin |
|
| February 2, 2023 |
EX-1.1 2 d456639dex11.htm EX-1.1 Exhibit 1.1 VERA THERAPEUTICS, INC. 14,285,715 Shares of Class A Common Stock Underwriting Agreement February 1, 2023 J.P. Morgan Securities LLC Cowen and Company, LLC Evercore Group L.L.C. As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Cowen and Company, LLC |
|
| February 2, 2023 |
Joint book-running managers J.P. Morgan Cowen Evercore ISI Lead manager LifeSci Capital Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-265408 Prospectus Supplement (To prospectus dated June 13, 2022) 14,285,715 Shares Class A common stock We are offering 14,285,715 shares of our Class A common stock. Our Class A common stock is traded on the Nasdaq Global Market under the symbol “VERA.” On February 1, 2023, the last reported sale price for our Class A common |
|
| February 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2023 Vera Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40407 81-2744449 (State or other jurisdiction of incorporation) (Commissio |
|
| February 1, 2023 |
Subject to completion, dated February 1, 2023 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-265408 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell |
|
| February 1, 2023 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2023 Vera Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40407 81-2744449 (State or other jurisdiction of incorporation) (Commissio |
|
| January 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2023 Vera Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40407 81-2744449 (State or other jurisdiction of incorporation) (Commissio |
|
| January 30, 2023 |
EX-99.1 © 2023 VERA THERAPEUTICS, INC. Phase 2b Clinical Trial Data Update January 30, 2023 Exhibit 99.1 Forward Looking Statements Disclaimer This material has been made available to you with the consent of Vera Therapeutics, Inc. ("we", "us", "our", or the "Company"). Statements contained in this presentation regarding matters, events or results that may occur in the future are “forward-looking |
|
| January 27, 2023 |
Exhibit 99.2 POWER OF ATTORNEY E. Merck KG, Darmstadt, Germany (the “Company”), hereby makes, constitutes and appoints each of Dr. Matthias Mülllenbeck, MBA, Jens Eckhardt, Kristin Eibisch and Johannes Eckhardt, or any of them acting singly, and with full power of substitution and re-substitution, the Company’s true and lawful attorney-in-fact (each of such persons and their substitutes being refe |
|
| January 27, 2023 |
VERA / Vera Therapeutics, Inc. Class A / Ares Trading S.A. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 1)* Vera Therapeutics, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 92337R101 (CUSIP Number) 31 December 2022 (Date |
|
| January 27, 2023 |
Exhibit 99.1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) of the Securities Exchange Act of 1934, as amended, each of the undersigned agrees to the joint filing on behalf of each of them of the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the share capital of Vera Therapeutics, Inc . This Joint Filing Agreement may be executed in counterparts and each o |
|
| January 3, 2023 |
© 2023 VERA THERAPEUTICS, INC. Phase 2b Clinical Trial Week 24 Results January 2023 EX-99.1 © 2023 VERA THERAPEUTICS, INC. Phase 2b Clinical Trial Week 24 Results January 2023 Forward Looking Statements Disclaimer This material has been made available to you with the consent of Vera Therapeutics, Inc. ("we", "us", "our", or the "Company"). Statements contained in this presentation regarding matters, events or results that may occur in the future are “forward-looking statements” w |
|
| January 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2023 Vera Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40407 81-2744449 (State or other jurisdiction of incorporation) (Commission |
|
| November 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2022 Vera Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40407 81-2744449 (State or other jurisdiction of incorporation) (Commissio |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40407 Vera |
|
| November 9, 2022 |
Vera Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results Exhibit 99.1 Vera Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results ? Phase 2b ORIGIN clinical trial of atacicept in IgA nephropathy (IgAN) topline data planned to be presented in early Q1 2023 ? Initiated the pivotal Phase 3 COMPASS clinical trial of atacicept in lupus nephritis ? Strong balance sheet with $114.4 million in cash, cash equivalents, and marketab |
|
| November 9, 2022 |
Exhibit 10.2 FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT This First Amendment to Loan and Security Agreement (this ?Amendment?) is entered into as of November 4, 2022, by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, VA 22314 (?Oxford?), as collateral agent (in such capacity, ?Collateral Agent?), the L |
|
| September 9, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2022 Vera Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40407 81-2744449 (State or other jurisdiction of incorporation) (Commissi |
|
| September 9, 2022 |
Exhibit 10.1 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark ?[***]?. Mr. Jay Bradner, M.D. President, Novartis Institutes for BioMedical Research c/o Novartis Pharma AG Licht |
|
| September 9, 2022 |
283,034 shares of Class A common stock Prospectus supplement September 9, 2022 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-265408 Prospectus supplement (To prospectus dated June 13, 2022) 283,034 shares of Class A common stock This prospectus supplement relates to the issuance of up to 283,034 shares of our Class A common stock. The shares may be issued pursuant to that certain License Agreement, dated August 26, 2019, as amended, or the License A |
|
| August 11, 2022 |
Exhibit 4 POWER OF ATTORNEY The undersigned understands that, from time to time, the Carlyle Companies (defined below) are required to prepare, execute, and file certain federal and state securities laws filings. |
|
| August 11, 2022 |
VERA / Vera Therapeutics, Inc. Class A / Carlyle Group Inc. - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Vera Therapeutics, Inc. (Name of Issuer) Class A Common Stock, par value $0.001 per share (Title of Class of Securities) 92337R101 (CUSIP Number) Jeffrey Ferguson The Carlyle Group 1001 Pennsylvania Avenue, NW Suite 220 South Washington, D.C. 20004 (202) 729-5626 (Nam |
|
| August 11, 2022 |
Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13D. |
|
| August 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2022 Vera Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40407 81-2744449 (State or other jurisdiction of incorporation) (Commission |
|
| August 10, 2022 |
Vera Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results Exhibit 99.1 Vera Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results • Completed enrollment for Phase 2b ORIGIN clinical trial of atacicept in IgA nephropathy; topline data now expected to be presented in early Q1 2023 • Presented positive 12-week interim analysis of Phase 2 study of MAU868 in kidney transplant recipients with BK Virus viremia at American Trans |
|
| August 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40407 Vera Thera |
|
| June 14, 2022 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-265408 Prospectus $400,000,000 Class A common stock Preferred stock Debt securities Warrants From time to time, we may offer up to $400,000,000 of any combination of the securities described in this prospectus in one or more offerings. We may also offer securities as may be issuable upon conversion, redemption, repurchase, exc |
|
| June 14, 2022 |
Class A common stock June 13, 2022 Filed Pursuant to Rule 424(b)(5) Registration No. 333-265408 Prospectus $150,000,000 Class A common stock We have entered into a sales agreement, or the sales agreement, with Cowen and Company, LLC, or Cowen, relating to shares of our Class A common stock offered by this prospectus. In accordance with the terms of the sales agreement, we may offer and sell shares of our Class A common stock having |
|
| June 9, 2022 |
Vera Therapeutics, Inc. 8000 Marina Boulevard, Suite 120 Brisbane, CA 94005 (650) 770-0077 Vera Therapeutics, Inc. 8000 Marina Boulevard, Suite 120 Brisbane, CA 94005 (650) 770-0077 June 9, 2022 VIA EDGAR Michael Davis United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Re: Vera Therapeutics, Inc. Registration Statement on Form S-3 (File No. 333-265408) Request for Acceleration of Effective Date Dear Mr. Davis: Pursuan |
|
| June 3, 2022 |
Form of Indenture, by and between the Registrant and one or more trustees to be named. Exhibit 4.3 VERA THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 20 Debt Securities TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee?s Certificate 7 Sec |
|
| June 3, 2022 |
Exhibit 1.2 VERA THERAPEUTICS, INC. $150,000,000 CLASS A COMMON STOCK SALES AGREEMENT June 3, 2022 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Vera Therapeutics, Inc. (the ?Company?), confirms its agreement (this ?Agreement?) with Cowen and Company, LLC (?Cowen?), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time during |
|
| June 3, 2022 |
As filed with the Securities and Exchange Commission on June 3, 2022 Table of Contents As filed with the Securities and Exchange Commission on June 3, 2022 Registration No. |
|
| June 3, 2022 |
Form of Class A Common Stock Warrant Agreement and Warrant Certificate. Exhibit 4.6 VERA THERAPEUTICS, Inc. AND , AS WARRANT AGENT FORM OF CLASS A COMMON STOCK WARRANT AGREEMENT DATED AS OF VERA THERAPEUTICS, INC. FORM OF CLASS A COMMON STOCK WARRANT AGREEMENT THIS CLASS A COMMON STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between VERA THERAPEUTICS, INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] o |
|
| June 3, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Vera Therapeutics, Inc. |
|
| June 3, 2022 |
Form of Debt Securities Warrant Agreement and Warrant Certificate. Exhibit 4.8 VERA THERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF VERA THERAPEUTICS, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between VERA THERAPEUTICS, INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organized and ex |
|
| June 3, 2022 |
Form of Preferred Stock Warrant Agreement and Warrant Certificate. Exhibit 4.7 VERA THERAPEUTICS, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF VERA THERAPEUTICS, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between VERA THERAPEUTICS, INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organized and ex |
|
| May 26, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2022 Vera Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40407 81-2744449 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 16, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2022 Vera Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40407 81-2744449 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 16, 2022 |
Vera Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results Exhibit 99.1 FOR IMMEDIATE RELEASE Vera Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results ? Phase 2b ORIGIN clinical trial of atacicept on track, topline data expected Q4 2022 ? Initiation of Phase 3 pivotal clinical trial of atacicept in lupus nephritis planned for 2H-2022, following positive clinical strategy meeting with FDA earlier this year ? Results from |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40407 Vera Ther |
|
| April 14, 2022 |
TABLE OF CONTENTS SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 14, 2022 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 7, 2022 Vera Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40407 81-2744449 (State or other jurisdiction of incorporation) (Commission F |
|
| April 7, 2022 |
VERA / Vera Therapeutics, Inc. Class A / Abingworth LLP - AMENDMENT NO.1 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) Vera Therapeutics, Inc. (Name of Issuer) Class A common stock, par value $0.001 per share (Title of Class of Securities) 92337R 101 (CUSIP Number) John Heard Abingworth LLP Princes House 38 Jermyn Street London, England SW1Y 6DN +44 20 7534 1500 (Name, Ad |
|
| April 5, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) VERA THERAPEUTICS, INC. (Name of Issuer) Class A Common Stock, $0.001 par value per share (Title of Class of Securities) 92337R101 (CUSIP Number) Patrick G. Enright Managing Member Longitude Capital Partners IV, LLC 2740 Sand Hill Road, 2nd Floor Menlo Park, CA 94025 ( |
|
| March 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K . UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 001-40407 Vera Therapeu |
|
| March 28, 2022 |
As filed with the Securities and Exchange Commission on March 28, 2022 As filed with the Securities and Exchange Commission on March 28, 2022 Registration No. |
|
| March 28, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Vera Therapeutics, Inc. |
|
| March 28, 2022 |
Description of Common Stock of the Registrant DESCRIPTION OF COMMON STOCK General The following description summarizes the terms of the Class A common stock and Class B common stock of Vera Therapeutics, Inc. |
|
| March 24, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 24, 2022 Vera Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40407 81-2744449 (State or other jurisdiction of incorporation) (Commission |
|
| March 24, 2022 |
Vera Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results Exhibit 99.1 FOR IMMEDIATE RELEASE Vera Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results ? Phase 2b ORIGIN clinical trial of atacicept on track, topline data expected Q4 2022 ? Acquired MAU868, a first-in-class monoclonal antibody to treat BK Virus infections, full results from interim analysis of Phase 2 study of MAU868 in kidney transplant recipients planned for mid-2022 |
|
| February 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* VERA THERAPEUTICS, INC. (Name of Issuer) Class A Common Stock, par value $0.001 per share (Title of Class of Securities) 92337R101 (CUSIP Number) February 14, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2 (Amendment No. 1)* Vera Therapeutics, Inc. (Name of Issuer) Class A common stock, par value $0.001 per share (the ?Shares?) (Title of Class of Securities) 923 |
|
| February 11, 2022 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. )* Vera Therapeutics, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 92337R101 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing |
|
| February 11, 2022 |
Figure A: Vera therapeutics pipeline Table of Contents Filed Pursuant to Rule 424(b)(4) Registration Nos. 333-262569 and 333-262618 Prospectus 4,993,067 shares Class A common stock We are offering 4,993,067 shares of our Class A common stock. Our Class A common stock is listed on the Nasdaq Global Market under the symbol ?VERA.? On February 9, 2022, the last reported sale price of our Class A common stock on the Nasdaq Global Market |
|
| February 10, 2022 |
As filed with the Securities and Exchange Commission on February 10, 2022. As filed with the Securities and Exchange Commission on February 10, 2022. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Vera Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 81-2744449 (State or other jurisdiction of incorporation or organization) |
|
| February 10, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-1 (Form Type) Vera Therapeutics, Inc. |
|
| February 7, 2022 |
Exhibit 10.16 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark ?[***]?. EXECUTION VERSION LICENSE AGREEMENT This License Agreement (?Agreement?), made as of August 26, 2019 (?E |
|
| February 7, 2022 |
VERA THERAPEUTICS, INC. 8000 Marina Boulevard, Suite 120 Brisbane, CA 94005 VERA THERAPEUTICS, INC. 8000 Marina Boulevard, Suite 120 Brisbane, CA 94005 February 7, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F. Street N.E. Washington, D.C. 20549-3010 Attn: Jeffrey Gabor RE: Vera Therapeutics, Inc. Registration Statement on Form S-1 (File No. 333-262569) Request for Acceleration of Effective Date Dear Mr. Gabor: Pursu |
|
| February 7, 2022 |
Exhibit 10.14 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (as the same may from time to time be amended, modified, supplemented or restated, this ?Agreement?) dated as of December 17, 2021 (the ?Effective Date?) among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, VA 22314 (?Oxford?), as collateral |
|
| February 7, 2022 |
Form of Underwriting Agreement. Exhibit 1.1 VERA THERAPEUTICS, INC. [ ] Shares of Class A Common Stock Underwriting Agreement [ ], 2022 J.P. Morgan Securities LLC Cowen and Company, LLC Evercore Group L.L.C. As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Cowen and Company, LLC 599 Lexington Avenue New York, New York 10012 a |
|
| February 7, 2022 |
EX-10.15 5 d210084dex1015.htm EX-10.15 Exhibit 10.15 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. Execution Copy ASSET PURCHASE AGREEMENT This Asset Purchase Agree |
|
| February 7, 2022 |
Exhibit 10.17 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark ?[***]?. AMENDMENT NO. 1 TO LICENSE AGREEMENT This Amendment No. 1 to the License Agreement, dated as of Septembe |
|
| February 7, 2022 |
February 7, 2022 VIA EDGAR Jeffrey Gabor U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Re: Registration Statement on Form S-1 (No. 333-262569) of Vera Therapeutics, Inc. Dear Mr. Gabor: In connection with the above-referenced Registration Statement, and pursuant to Rule 461 under the Securities Act of 1933, as amended (the ?Act?), we |
|
| February 7, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-1 (Form Type) Vera Therapeutics, Inc. |
|
| February 7, 2022 |
Table of Contents As filed with the Securities and Exchange Commission on February 7, 2022. |
|
| January 24, 2022 |
VERA / Vera Therapeutics, Inc. Class A / Ares Trading S.A. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. )* Vera Therapeutics, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 92337R101 (CUSIP Number) 31 December 2021 (Date |
|
| January 4, 2022 |
Confidential Treatment Requested by Vera Therapeutics, Inc. Pursuant to 17 C.F.R. § 200.83 Confidential Treatment Requested by Vera Therapeutics, Inc. Pursuant to 17 C.F.R. ? 200.83 Exhibit 10.17 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark ?[***]?. AMENDMENT NO. |
|
| January 4, 2022 |
Confidential Treatment Requested by Vera Therapeutics, Inc. Pursuant to 17 C.F.R. § 200.83 Confidential Treatment Requested by Vera Therapeutics, Inc. Pursuant to 17 C.F.R. ? 200.83 Exhibit 10.16 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark ?[***]?. EXECUTION VER |
|
| January 4, 2022 |
Confidential Treatment Requested by Vera Therapeutics, Inc. Pursuant to 17 C.F.R. § 200.83 Confidential Treatment Requested by Vera Therapeutics, Inc. Pursuant to 17 C.F.R. ? 200.83 Exhibit 10.15 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark ?[***]?. Execution Cop |
|
| January 4, 2022 |
Table of Contents Confidential Treatment Requested by Vera Therapeutics, Inc. Pursuant to 17 C.F.R. ? 200.83 As confidentially submitted to the Securities and Exchange Commission on January 3, 2022. This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential. Registration No. 333- UNITED STATES S |
|
| January 4, 2022 |
Confidential Treatment Requested by Vera Therapeutics, Inc. Pursuant to 17 C.F.R. § 200.83 Confidential Treatment Requested by Vera Therapeutics, Inc. Pursuant to 17 C.F.R. ? 200.83 Exhibit 10.14 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (as the same may from time to time be amended, modified, supplemented or restated, this ?Agreement?) dated as of December 17, 2021 (the ?Effective Date?) among OXFORD FINANCE LLC, a Delaware limited liability company with an office lo |
|
| December 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2021 Vera Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40407 81-2744449 (State or other jurisdiction of incorporation) (Commissi |
|
| December 17, 2021 |
Exhibit 99.1 Vera Therapeutics Announces Acquisition of Monoclonal Antibody From Pfizer to Treat BK Virus in Transplant Patients Ongoing Phase 2 clinical trial for MAU868 in kidney transplant patients; potential first-in-class MAU868 Phase 2 data for kidney transplant to readout mid-2022 BK Virus is a leading cause of transplant loss and transplant-associated morbidity BRISBANE, Calif., December 1 |
|
| December 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2021 Vera Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40407 81-2744449 (State or other jurisdiction of incorporation) (Commissi |
|
| November 10, 2021 |
Vera Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update Exhibit 99.1 FOR IMMEDIATE RELEASE Vera Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update ? Company makes ongoing progress in several areas evaluating atacicept, its lead product candidate ? Phase 2a JANUS clinical trial showed atacicept administered subcutaneously once weekly demonstrated a durable and substantial reduction in serum galactose-deficient IgA1 ( |
|
| November 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 Vera Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40407 81-2744449 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40407 Vera |
|
| August 16, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| August 16, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2021 Vera Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40407 81-2744449 (State or other jurisdiction of incorporation) (Commission |
|
| August 16, 2021 |
Vera Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update - - - Exhibit 99.1 FOR IMMEDIATE RELEASE Vera Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update - - - SOUTH SAN FRANCISCO, Calif., August 16, 2021 ? Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing treatments for immunological diseases that improve patients? lives, today reported its financial results for the seco |
|
| July 14, 2021 |
Exhibit 10.1 May 30, 2021 Sean P. Grant Re: Employment Terms Dear Sean: On behalf of Vera Therapeutics, Inc. (the ?Company?), I am pleased to offer you employment at the Company on the terms set forth in this offer letter agreement (this ?Agreement?). As discussed, the terms of this Agreement govern with respect to your employment, which shall commence on a mutually agreed upon date that is no lat |
|
| July 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2021 Vera Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40407 81-2744449 (State or other jurisdiction of incorporation) (Commission F |
|
| June 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| June 24, 2021 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Vera Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update - - - Completed an initial public offering with net proceeds, including the exercise of the underwriters? option in full, of approximately $48.4 million in May 2021 - - - Expanded the management team to support initiation of atacicept clinical development program - - - In |
|
| June 24, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2021 Vera Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40407 81-2744449 (State or other jurisdiction of incorporation) (Commission F |
|
| May 28, 2021 |
VERA / Vera Therapeutics, Inc. Class A / CITADEL ADVISORS LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G*/ (Rule 13d-102) Under the Securities Exchange Act of 1934 (Amendment No. )* Vera Therapeutics, Inc. (Name of Issuer) Class A common stock, par value $0.001 per share (Title of Class of Securities) 92337R101 (CUSIP Number) May 18, 2021 Date of Event Which Requires Filing of the Statement Check the appropriate box |
|
| May 28, 2021 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the Class A common stock of Vera Therapeutics, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each |
|
| May 27, 2021 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned, and any amendments thereto executed by the undersigned shall be filed on behalf of each of the undersigned without the necessity of filing any additional joint filing agreement. |
|
| May 27, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) VERA THERAPEUTICS, INC. (Name of Issuer) Class A Common Stock, $0.001 par value per share (Title of Class of Securities) 92337R101 (CUSIP Number) Patrick G. Enright Managing Member Longitude Capital Partners IV, LLC 2740 Sand Hill Road, 2nd Floor Menlo Park, CA 94025 (6 |
|
| May 24, 2021 |
Exhibit 1 JOINT FILING AGREEMENT This Agreement will confirm the agreement by and among the undersigned that the Schedule 13D filed with the Securities and Exchange Commission on the date hereof with respect to the beneficial ownership by the undersigned of the Common Shares of Vera Therapeutics, Inc. |
|
| May 24, 2021 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (RULE 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. )* Vera Therapeutics, Inc. (Name of Issuer) Class A Common Stock, $0.001 par value (Title of Class of Securities) 92337R101 (CUSIP Number) Nathalie Auber Sofinnova Investm |
|
| May 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Vera Therapeutics, Inc. (Name of Issuer) Class A Common Stock, par value $0.001 per share (Title of Class of Securities) 92337R 101 (CUSIP Number) John Heard Abingworth LLP Princes House 38 Jermyn Street London, England SW1Y 6DN +44 20 7534 1500 (Name, Address and Telephon |
|
| May 18, 2021 |
Exhibit 3.1 FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF VERA THERAPEUTICS, INC. Vera Therapeutics, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of the Delaware (the ?DGCL?), hereby certifies that: ONE: The name of this corporation is Vera Therapeutics, Inc. The original name of this corporation was CDF Therapeutics, Inc. |
|
| May 18, 2021 |
As filed with the Securities and Exchange Commission on May 18, 2021 As filed with the Securities and Exchange Commission on May 18, 2021 Registration No. |
|
| May 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2021 Vera Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40407 81-2744449 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 18, 2021 |
Exhibit 3.2 THIRD AMENDED AND RESTATED BYLAWS OF VERA THERAPEUTICS, INC. (A DELAWARE CORPORATION) May 18, 2021 Table of Contents Page ARTICLE I OFFICES 1 Section 1. Registered Office 1 Section 2. Other Offices 1 ARTICLE II CORPORATE SEAL 1 Section 3. Corporate Seal 1 ARTICLE III STOCKHOLDERS? MEETINGS 1 Section 4. Place of Meetings 1 Section 5. Annual Meetings 2 Section 6. Special Meetings 5 Secti |
|
| May 17, 2021 |
4,350,000 Shares Class A Common Stock Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-255492 PROSPECTUS 4,350,000 Shares Class A Common Stock This is an initial public offering of shares of Class A common stock by Vera Therapeutics, Inc. We are offering 4,350,000 shares of our Class A common stock. The initial public offering price is $11.00 per share. Prior to this offering, there has been no public market for |
|
| May 12, 2021 |
May 12, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Dillon Hagius Irene Paik Christie Wong Vanessa Robertson Re: Vera Therapeutics, Inc. Registration Statement on Form S-1 Registration No. 333-255492 Acceleration Request Requested Date: May 13, 2021 Requested Time: 4:30 PM, Eastern Time Ladies and Gentl |
|
| May 12, 2021 |
As filed with the Securities and Exchange Commission on May 12, 2021. Table of Contents As filed with the Securities and Exchange Commission on May 12, 2021. |
|
| May 12, 2021 |
VERA THERAPEUTICS, INC. 170 Harbor Way, 3rd Floor South San Francisco, CA 94080 VERA THERAPEUTICS, INC. 170 Harbor Way, 3rd Floor South San Francisco, CA 94080 May 12, 2021 VIA EDGAR Securities and Exchange Commission Office of Finance Division of Corporation Finance 100 F. Street N.E. Washington, D.C. 20549-3010 Attn: Dillon Hagius Irene Paik Christie Wong Vanessa Robertson RE: Vera Therapeutics, Inc. Registration Statement on Form S-1, as amended (File No. 333-255492) Reque |
|
| May 12, 2021 |
Jodie Bourdet +1 (415) 693-2054 [email protected] Via EDGAR May 12, 2021 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Dillon Hagius Irene Paik Christie Wong Vanessa Robertson Re: Vera Therapeutics, Inc. Registration Statement on Form S-1 Filed April 23, 2021 File No. 333-255492 Ladies and Gentlemen: On behalf of Vera Ther |
|
| May 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(B) OR (G) OF THE SECURITIES EXCHANGE ACT OF 1934 Vera Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 81-2744449 (State of Incorporation or Organization) (I.R.S. Employer Identification No.) 170 Harbor Way, 3rd |
|
| May 10, 2021 |
Exhibit 4.1 VT INCORPORATED UNDER THE CUSIP 92337R 10 1 LAWS OF THE STATE SEE REVERSE FOR CERTAIN OF DELAWARE DEFINITIONS AND LEGENDS This certifies that BY: AMERICAN COUNTERSIGNED is the record holder of STOCK AND FULLY PAID AND NONASSESSABLE SHARES OF CLASS A COMMON STOCK, $0.001 PAR VALUE PER SHARE, OF (BROOKLYN, VERA THERAPEUTICS, INC. TRANSFER transferable on the books of the Corporation in p |
|
| May 10, 2021 |
Exhibit 10.5 VERA THERAPEUTICS, INC. 2021 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT GRANT NOTICE Vera Therapeutics, Inc. (the ?Company?) has awarded to you (the ?Participant?) the number of restricted stock units specified and on the terms set forth below in consideration of your services (the ?RSU Award?). Your RSU Award is subject to all of the terms and conditions as set forth herein and in t |
|
| May 10, 2021 |
Form of Underwriting Agreement. Exhibit 1.1 [ ] Shares Vera Therapeutics, Inc. UNDERWRITING AGREEMENT [ ], 2021 JEFFERIES LLC COWEN AND COMPANY, LLC EVERCORE GROUP L.L.C. As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o COWEN AND COMPANY, LLC 599 Lexington Avenue New York, New York 10012 c/o EVERCORE GROUP L.L.C. 55 East 52nd Street, Ste 35 New York, New York 10055 |
